Braingrid Limited (CSE:BGRD) (“Braingrid”), a global provider of affordable, scalable and easy-to-deploy sensor platforms for real-time data collection in Precision Agriculture, is pleased to announce that it has launched its new low-cost Data Analytics Program called Braingrid Data Intelligence. Reports generated under this program will provide growers with unprecedented conclusions on yield variances and leading indicators of pathogen risks before the actual outbreak occurs.

Braingrid Plant Data Scientist Dr. Vanessa Nielsen will lead the team responsible for producing all reports to cannabis customers. Dr. Nielsen commented “Our customers have always struggled with having sufficient time and expertise to analyze the mountain of data surrounding each batch. Now we will do the heavy lifting for them by digging into their grow details to discover hidden gems of information showing comparative batch-to-batch variations.”


As the “mobile field lab” supplier of real-time data, Braingrid becomes a valuable information partner providing new grow foresight.

Six reports are currently available to Braingrid customers: Anomaly Analysis for Temperature, Humidity, and CO2, Powdery Mildew and Spider Mite Scores, and Vapor Pressure Deficit Chart Analytics. More reports to be announced soon.

Braingrid’s recent agreement with integration partner A&L Canada Laboratories Inc. (“A&L”) will expand delivery of their tests such as Plant Tissue Reports to be part of Braingrid Data Intelligence. Nevin McDougall, President and Chief Commercial Officer of A&L, said: “Braingrid’s new analytical reports take the science of growing to a whole new level which, when combined with our various tests to confirm pathogens or fertility issues, give the grower unprecedented depth of knowledge and foresight.” The grower can then address the issue at hand and use this data in the next grow cycle for an even higher level of success. Anyone can grow a crop however A & L Canada Laboratories agronomy knowledge & testing services assists growers to achieve a higher yielding quality crop based on their specific goals.

Derek Pedro, Chief Cannabis Officer at WeedMD, commented: “Braingrid has been a valuable partner to WeedMD for years. These new reports provide a quick synopsis of detailed information over a period of months and years that was never before available to us, making what we do here more effective. We really appreciate this new view of our facility operation.”

Early indications from new and existing Braingrid customers show overwhelming support for these new low-cost reports. The Braingrid Data Intelligence program will be showcased at the upcoming O’Cannabiz Conference & Expo in Toronto on April 25-27, 2019.

Media Contact:

Braingrid- Doug Harris
Chief Financial Officer
416-480-2488
ir@braingrid.io
www.braingrid.io

About Braingrid:

Braingrid is a global technology company committed to the best interests of the precision agriculture industry for the long term. We provide valuable grow information by capturing real-time data using our technology platform to increase revenues, reduce costs, risks and improve yield – making it easier for the grower to operate efficiently and effectively. Braingrid is providing the cannabis industry with powerful technologies, now and into the future. The Company is listed on the CSE under the symbol BGRD.

FORWARD-LOOKING INFORMATION

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of Braingrid. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of Braingrid to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although Braingrid believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, Braingrid assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/1435/44133_857976a214b6298c_001full.jpg

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/1435/44133_857976a214b6298c_001full.jpg

Source: www.newsfilecorp.com

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less